Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles
ABSTRACTCoxsackievirus B4 (CVB4) is associated with a range of acute and chronic diseases such as hand, foot, and mouth disease, myocarditis, meningitis, pancreatitis, and type 1 diabetes, affecting millions of young children annually around the world. However, no vaccine is currently available for...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2024.2337665 |
| _version_ | 1827292353895858176 |
|---|---|
| author | Tingfeng Wang Chiyuan Wang Lili Pang Yujie Zhang Shuxia Wang Xiaozhen Liang Zhong Huang |
| author_facet | Tingfeng Wang Chiyuan Wang Lili Pang Yujie Zhang Shuxia Wang Xiaozhen Liang Zhong Huang |
| author_sort | Tingfeng Wang |
| collection | DOAJ |
| description | ABSTRACTCoxsackievirus B4 (CVB4) is associated with a range of acute and chronic diseases such as hand, foot, and mouth disease, myocarditis, meningitis, pancreatitis, and type 1 diabetes, affecting millions of young children annually around the world. However, no vaccine is currently available for preventing CVB4 infection. Here, we report the development of inactivated viral particle vaccines for CVB4. Two types of inactivated CVB4 particles were prepared from CVB4-infected cell cultures as vaccine antigens, including F-particle (also called mature virion) consisting of VP1, VP3, VP2, and VP4 subunit proteins, and E-particle (also called empty capsid) which is made of VP1, VP3, and uncleaved VP0. Both the inactivated CVB4 F-particle and E-particle were able to potently elicit neutralizing antibodies in mice, despite slightly lower neutralizing antibody titres seen with the E-particle vaccine after the third immunization. Importantly, we demonstrated that passive transfer of either anti-F-particle or anti-E-particle sera could completely protect the recipient mice from lethal CVB4 challenge. Our study not only defines the immunogenicity and protective efficacy of inactivated CVB4 F-particle and E-particle but also reveals the central role of neutralizing antibodies in anti-CVB4 protective immunity, thus providing important information that may accelerate the development of inactivated CVB4 vaccines. |
| first_indexed | 2024-04-24T13:02:03Z |
| format | Article |
| id | doaj.art-9ce9ae4482e945d0adb1ababd29bff1a |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-04-24T13:02:03Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-9ce9ae4482e945d0adb1ababd29bff1a2024-04-05T10:25:43ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512024-12-0113110.1080/22221751.2024.2337665Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particlesTingfeng Wang0Chiyuan Wang1Lili Pang2Yujie Zhang3Shuxia Wang4Xiaozhen Liang5Zhong Huang6Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaShanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of ChinaShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of ChinaShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of ChinaShanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, People’s Republic of ChinaShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of ChinaABSTRACTCoxsackievirus B4 (CVB4) is associated with a range of acute and chronic diseases such as hand, foot, and mouth disease, myocarditis, meningitis, pancreatitis, and type 1 diabetes, affecting millions of young children annually around the world. However, no vaccine is currently available for preventing CVB4 infection. Here, we report the development of inactivated viral particle vaccines for CVB4. Two types of inactivated CVB4 particles were prepared from CVB4-infected cell cultures as vaccine antigens, including F-particle (also called mature virion) consisting of VP1, VP3, VP2, and VP4 subunit proteins, and E-particle (also called empty capsid) which is made of VP1, VP3, and uncleaved VP0. Both the inactivated CVB4 F-particle and E-particle were able to potently elicit neutralizing antibodies in mice, despite slightly lower neutralizing antibody titres seen with the E-particle vaccine after the third immunization. Importantly, we demonstrated that passive transfer of either anti-F-particle or anti-E-particle sera could completely protect the recipient mice from lethal CVB4 challenge. Our study not only defines the immunogenicity and protective efficacy of inactivated CVB4 F-particle and E-particle but also reveals the central role of neutralizing antibodies in anti-CVB4 protective immunity, thus providing important information that may accelerate the development of inactivated CVB4 vaccines.https://www.tandfonline.com/doi/10.1080/22221751.2024.2337665Coxsackievirus B4inactivated vaccineE-particleF-particleneutralizing antibodyvirus challenge |
| spellingShingle | Tingfeng Wang Chiyuan Wang Lili Pang Yujie Zhang Shuxia Wang Xiaozhen Liang Zhong Huang Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles Emerging Microbes and Infections Coxsackievirus B4 inactivated vaccine E-particle F-particle neutralizing antibody virus challenge |
| title | Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles |
| title_full | Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles |
| title_fullStr | Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles |
| title_full_unstemmed | Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles |
| title_short | Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles |
| title_sort | immunogenicity and protective efficacy of inactivated coxsackievirus b4 viral particles |
| topic | Coxsackievirus B4 inactivated vaccine E-particle F-particle neutralizing antibody virus challenge |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2024.2337665 |
| work_keys_str_mv | AT tingfengwang immunogenicityandprotectiveefficacyofinactivatedcoxsackievirusb4viralparticles AT chiyuanwang immunogenicityandprotectiveefficacyofinactivatedcoxsackievirusb4viralparticles AT lilipang immunogenicityandprotectiveefficacyofinactivatedcoxsackievirusb4viralparticles AT yujiezhang immunogenicityandprotectiveefficacyofinactivatedcoxsackievirusb4viralparticles AT shuxiawang immunogenicityandprotectiveefficacyofinactivatedcoxsackievirusb4viralparticles AT xiaozhenliang immunogenicityandprotectiveefficacyofinactivatedcoxsackievirusb4viralparticles AT zhonghuang immunogenicityandprotectiveefficacyofinactivatedcoxsackievirusb4viralparticles |